Ustekinumab and Janus Kinase Inhibitors Outperform Vedolizumab as Second-Line Therapy in Anti-Tumor Necrosis Factor-Experienced Patients With Ulcerative Colitis
Giuseppe Privitera, Cristina Bezzio, Gisella Figlioli, Ferdinando D’Amico et autres
it, pt, es, gr, il, us (code pays fourni par la source)